Uppsala, Sweden – July 4, 2017 – As previously communicated Orexo will announce the Interim Report for the second quarter 2017 on Tuesday July 11 at 8.00 am CET. The same day at 2.00 pm CET analysts, investors and media are invited to attend an audiocast with a web presentation where CEO, Nikolaj Sørensen, and CFO, Henrik Juuel, will present the report. After the presentation a Q&A will be held. Questions can also be sent in advance to email@example.com, no later than 11.00 am CET.
Please view the instructions below on how to participate.
Internet link: https://tv.streamfabriken.com/orexo-q2-2017
Telephone: (SE) +46 8 566 426 92, (UK) +44 20 300 89 807 or (US) +1 855 831 5945
The presentation material will be available on Orexo´s website one hour prior to the audiocast.
For further information, please contact:
Orexo AB (publ.)
Lena Wange, IR and Communications Manager
Tel: + 46 (0)18 780 88 00
Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The main market today is the US market for the treatment of opioid dependence where the product Zubsolv® is commercialized by Orexo. Other products are commercialized by license partners, including Zubsolv in markets outside of the US. Total net sales for 2016 amounted to SEK 705.9 million and the number of employees was 102. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) index and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where also research and development is performed, is located in Uppsala, Sweden.
For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube. For more information about Zubsolv in the US, see the product and market websites www.zubsolv.com and www.rise-us.com.